Christopher G. Slatore, MD, MS, David H

Slides:

Advertisements

Similar presentations

Choroidal Metastases Responsive to Crizotinib Therapy in a Lung Adenocarcinoma Patient with ALK 2p23 Fusion Identified by ALK Immunohistochemistry Yan.

Advertisements

Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel, Carboplatin, and Bevacizumab in First-line Patients with Advanced Nonsquamous Non-small Cell.

Su K. Metcalfe, MD, MPH, Michael T

Differences in Primary Care Clinicians' Approach to Non-small Cell Lung Cancer Patients Compared with Breast Cancer Timothy R. Wassenaar, MD, Jens C.

Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies Sai-Hong Ignatius Ou, MD,

Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.

Characteristics and Outcomes of Small Cell Lung Cancer Patients Diagnosed During Two Lung Cancer Computed Tomographic Screening Programs in Heavy Smokers

The eighth edition TNM stage classification for lung cancer: What does it mean on main street? Frank C. Detterbeck, MD The Journal of Thoracic and Cardiovascular.

Impact of Race on Outcomes of Patients with Non-small Cell Lung Cancer

One in every 14 patients with early-stage lung cancer is not being treated! Benny Weksler, MD, MBA The Journal of Thoracic and Cardiovascular Surgery

Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer Sai-Hong Ignatius Ou, MD, PhD, Jason.

Disparities in Treatment of Patients with Inoperable Stage I Non–Small Cell Lung Cancer: A Population-Based Analysis Matthew Koshy, MD, Renuka Malik,

ALK FISH and IHC: You Cannot Have One without the Other

Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy

Ellen M. Schultz, MS, Gerard A. Silvestri, MD, MS, Michael K

Gemcitabine and Irinotecan for Patients with Untreated Extensive Stage Small Cell Lung Cancer: SWOG 0119 Wallace Akerley, MD, Jason McCoy, MS, Paul J.

Electronic Updates for JTO Readers

Timing of Local and Distant Failure in Resected Lung Cancer: Implications for Reported Rates of Local Failure Jessamy A. Boyd, MD, Jessica L. Hubbs,

The International Association for the Study of Lung Cancer International Staging Project on Lung Cancer Peter Goldstraw, MB, FRCS, John J. Crowley, PhD

A Pharmacogenomic Study of Docetaxel and Gemcitabine for the Initial Treatment of Advanced Non-Small Cell Lung Cancer W Jeffrey Petty, MD, Sommer N.

Samuel J. Wang, MD, PhD, C David Fuller, MD, Charles R. Thomas, MD

Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.

Differences in Primary Care Clinicians' Approach to Non-small Cell Lung Cancer Patients Compared with Breast Cancer Timothy R. Wassenaar, MD, Jens C.

Frank Detterbeck, MD Journal of Thoracic Oncology

Philip W. Smith, MD, Hongkun Wang, PhD, Leo M. Gazoni, MD, K

Phase II Trial of Paclitaxel and Cisplatin in Patients with Extensive Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Trial 9430 Thomas E.

Mediastinal Lymph Node Examination and Survival in Resected Early-Stage Non– Small-Cell Lung Cancer in the Surveillance, Epidemiology, and End Results.

Second-line or Subsequent Systemic Therapy for Recurrent or Progressive Non-Small Cell Lung Cancer: A Systematic Review and Practice Guideline J Noble,

Intratumoral Lymphatic Vessel Involvement is an Invasive Indicator of Completely Resected Pathologic Stage I Non-small Cell Lung Cancer Masahiko Harada,

Effects of Chemotherapy on Survival of Elderly Patients with Small-Cell Lung Cancer: Analysis of the SEER-Medicare Database Laura C. Caprario, MD, MS,

Elizabeth A. David, MD, MAS, Stina W. Andersen, PhD, Laurel A

Treatment trends in early-stage lung cancer in the United States, 2004 to 2013: A time- trend analysis of the National Cancer Data Base Kathryn E. Engelhardt,

Socioeconomic Status Is Associated with Depressive Severity Among Patients with Advanced Non–Small-Cell Lung Cancer: Treatment Setting and Minority Status.

Elizabeth B. Gottlin, PhD, Rex C. Bentley, MD, Michael J

A Phase II Study of Paclitaxel + Etoposide + Cisplatin + Concurrent Radiation Therapy for Previously Untreated Limited Stage Small Cell Lung Cancer (E2596):

Chemotherapy in Patients ≥80 with Advanced Non-small Cell Lung Cancer: Combined Results from SWOG 0027 and LUN 6 Paul J. Hesketh, MD, Rogerio C. Lilenbaum,

Jeffrey T. Yorio, MD, Yang Xie, PhD, Jingsheng Yan, PhD, David E

Daniel Morgensztern, MD, Boone Goodgame, MD, Maria Q

Impact of positive pleural lavage cytology on survival in patients having lung resection for non–small-cell lung cancer: An international individual patient.

Appropriateness of Surgical Approach in Black Patients with Lung Cancer—15 Years Later, Little Has Changed Emanuela Taioli, MD, PhD, Raja Flores, MD

Positron Emission Tomography 18F-Fluorodeoxyglucose Uptake and Prognosis in Patients with Surgically Treated, Stage I Non-small Cell Lung Cancer: A Systematic.

Five-Year Outcome of Lung Cancer Detection in Patients With and Without Airflow Obstruction in a Primary Care Outpatient Practice Joel J. Bechtel, MD,

A Translational View of the Molecular Pathogenesis of Lung Cancer

Clinical Utility of the Pretreatment Glasgow Prognostic Score in Patients with Advanced Inoperable Non-small Cell Lung Cancer Elaine Y.L. Leung, MB ChB,

Mirror Mirror on the Wall, Who Is the Fairest of Them All

Defining Local-Regional Control and Its Importance in Locally Advanced Non-small Cell Lung Carcinoma Mitchell Machtay, MD, Rebecca Paulus, BS, Jennifer.

Trends in Stage Distribution for Patients with Non-small Cell Lung Cancer: A National Cancer Database Survey Daniel Morgensztern, MD, Shean Huey Ng,

The Prognostic Impact of Cigarette Smoking on Patients with Non-small Cell Lung Cancer Ryo Maeda, MD, Junji Yoshida, MD, PhD, Genichiro Ishii, MD, PhD,

Immune-Modulating Vaccines in Non-small Cell Lung Cancer

T4 or MI? Journal of Thoracic Oncology Volume 6, Issue 3, (March 2011)

Video-assisted resection for lung cancer results in fewer complications Lunxu Liu, PhD, MD, FRCS The Journal of Thoracic and Cardiovascular Surgery

Prognosis of Resected Non-Small Cell Lung Cancer Patients with Intrapulmonary Metastases Kanji Nagai, MD, Yasunori Sohara, MD, Ryosuke Tsuchiya, MD,

Jie Huang, Juan Peng, Linlang Guo, MD, PhD

Significance of Smoking as a Postoperative Prognostic Factor in Patients with Non- small Cell Lung Cancer Takeshi Hanagiri, MD, PhD, Kenji Sugio, MD,

Ethnic Differences in the Management of Lung Cancer in New Zealand

BRIDGE: An Open-Label Phase II Trial Evaluating the Safety of Bevacizumab + Carboplatin/Paclitaxel as First-Line Treatment for Patients with Advanced,

Roger Hakimian, MD, Hongbin Fang, PhD, Leno Thomas, MD, Martin J

European Lung Cancer Conference (ELCC) 2016 Organisation

Stage I Non-small Cell Lung Cancer: Results for Surgery in a Patterns-of-Care Study in Sydney and for High-Dose Concurrent End-Phase Boost Accelerated.

Bryan M. Burt, MD The Journal of Thoracic and Cardiovascular Surgery

Discussion The Journal of Thoracic and Cardiovascular Surgery

Wedge Resection for Non-small Cell Lung Cancer in Patients with Pulmonary Insufficiency: Prospective Ten-Year Survival John P. Griffin, MD, Charles E.

Robert J. Cerfolio, MD, FACS, FCCP, Ayesha S. Bryant, MSPH, MD

Jamie E. Chaft, MD, Camelia S. Sima, MD, MS, Michelle S

Sorafenib in Platinum-Treated Patients with Extensive Stage Small Cell Lung Cancer: A Southwest Oncology Group (SWOG 0435) Phase II Trial Barbara J.

Impact of Information on Quality of Life and Satisfaction of Non-small Cell Lung Cancer Patients: A Randomized Study of Standardized versus Individualized.

Rogerio C. Lilenbaum, MD, John Cashy, PhD, Thomas A

Effect of Tumor Size on Prognosis in Patients Treated with Radical Radiotherapy or Chemoradiotherapy for Non–Small Cell Lung Cancer: An Analysis of the.

A Review of First-Line Treatment for Small-cell Lung Cancer

Razvan Diaconescu, MD, Chantal Lafond, MD, Renaud Whittom, MD

Presentation transcript:

Cost-Effectiveness of a Smoking Cessation Program Implemented at the Time of Surgery for Lung Cancer Christopher G. Slatore, MD, MS, David H. Au, MD, MS, William Hollingworth, PhD Journal of Thoracic Oncology Volume 4, Issue 4, Pages 499-504 (April 2009) DOI: 10.1097/JTO.0b013e318195e23a Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 1 It shows the decision tree developed from the available evidence. Patients diagnosed with resectable stage IIIB or less non-small cell lung cancer are offered a smoking cessation program or usual care. Each number represents the probability of progressing to one stage or the other. Periop, perioperative. Journal of Thoracic Oncology 2009 4, 499-504DOI: (10.1097/JTO.0b013e318195e23a) Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 2 It shows the 5-year postsurgery differences in cost/quality adjusted life years (QALY) and cost/life year as the proportion of recent quitters who suffer perioperative complications increases over the rate of continued smokers with perioperative complications. Note that the base case assumes no difference in the proportions suffering perioperative complications. Journal of Thoracic Oncology 2009 4, 499-504DOI: (10.1097/JTO.0b013e318195e23a) Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 3 It shows the 5-year postsurgery differences in cost/quality adjusted life years (QALY) and cost/life year as the cost of the smoking cessation program changes. Note that the base case has a cost of approximately $200. Journal of Thoracic Oncology 2009 4, 499-504DOI: (10.1097/JTO.0b013e318195e23a) Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 4 It shows the 5-year postsurgery differences in cost/quality adjusted life years (QALY) and cost/life year as the effectiveness of the smoking cessation program changes. Note that the base case assumes the smoking cessation program leads to an increase of 7% of the subjects achieving abstinence at 3 months postsurgery. Journal of Thoracic Oncology 2009 4, 499-504DOI: (10.1097/JTO.0b013e318195e23a) Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 5 It shows the 5-year postsurgery differences in cost/quality adjusted life years (QALY) and cost/life year as the proportion of smokers who are deceased at 1 year after surgery increases over the proportion of recent quitters who are deceased. Note that the base case assumes that smokers have a 12% higher proportion who are deceased at 1 year compared with recent quitters. Journal of Thoracic Oncology 2009 4, 499-504DOI: (10.1097/JTO.0b013e318195e23a) Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 6 It shows the 5-year postsurgery differences in cost/quality adjusted life years (QALY) as the utility of smokers changes with respect to quitters. Note that the base case assumes that quitters have a utility score 0.15 higher than smokers. Journal of Thoracic Oncology 2009 4, 499-504DOI: (10.1097/JTO.0b013e318195e23a) Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions